Stay updated with breaking news from Davidj wambeke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings data on Monday, May 15th. The […] ....
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report) insider David J. Wambeke purchased 38,364 shares of the business’s stock in a transaction on Friday, June 23rd. The shares were bought at an average cost of $3.91 per share, for a total transaction of $150,003.24. Following the purchase, the insider now owns 507,114 shares of the company’s […] ....
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 38,364 shares of the stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $3.91 per share, with a total value of $150,003.24. Following the acquisition, the insider now owns 507,114 shares of the company’s stock, […] ....
DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […] ....
Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) were up 10.1% during mid-day trading on Monday . The company traded as high as $3.67 and last traded at $3.50. Approximately 190,500 shares were traded during trading, an increase of 269% from the average daily volume of 51,670 shares. The stock had previously closed at […] ....